#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
Tag: BRAF-mutated melanoma
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
First-line treatment with immune checkpoint inhibitor rather than BRAF and MEK leads to improved survival
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Encorafenib plus binimetinib improves quality of life outcomes compared to vemurafenib in patients with advanced BRAF-mutated melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.